Investing in new insecticides to combat malaria

Household spraying in Matabele North Province, Zimbabwe, near the northern border with Zambia. Spraying is done once a year to kill adult malarial mosquitoes (Image: John Rae/The Global Fund)

Accelerating uptake of new tools to prevent and manage insecticide resistance.

Challenges

Indoor residual spraying (IRS) – spraying the walls and eaves of dwellings with insecticides – is a tried and tested way of killing malarial mosquitoes, and controlling the disease. However, over time mosquitoes become resistant to the insecticides that they come into contact with most often. If unchecked, insecticide resistance could threaten gains against malaria.

IRS coverage has fallen by around 40 percent over the last few years due to resistance of mosquitoes to older products and to the higher cost of new alternatives.

Solutions

Only one next-generation IRS product is currently on the market. A key objective is to lower the price of the existing product and make it more widely available. A further aim is to get other new insecticidal products on the market, to support resistance management.

Over four years, the project aims to protect as many as 50 million people from malaria in 16 African countries.

Progress so far

In 2016, IVCC and partners successfully completed an annual spraying season in four countries using the new insecticide. New countries were identified for spraying during 2017, increasing the number of spraying programmes from four to twelve.

Update November 2017

The project is on track to achieve and exceed some of its 2017 targets. Through the first six months of 2017, this project:

  • Completed procurement of 1.65 million bottles of Actellic 300CS, the new insecticide for resistance management, for six countries: Benin, Ethiopia, Ghana, Kenya, Tanzania/Zanzibar and Uganda.
  • Has reversed the declining trend of the IRS market volume in Africa for the first time since 2013.
  • Provided technical support for new IRS products to enter the market, which increased market competition.
  • One of these – the new IRS product SumiShield by Sumitomo – was approved by WHO in October 2017.

This project is likely to exceed the 2017 procurement target of 2.7 million bottles of Actellic, protecting an estimated 52 million people from malaria, already double the end-of-project target of 26.1 million people protected.

The impact we are seeking

The overall impact of the grant is to create a more sustainable market for next-generation IRS products. This should contribute to bringing back IRS to historical coverage levels, and mitigating resistance to key insecticides. Over the long term, this will help to prevent more malaria cases, thereby saving lives and averting treatment costs.



Related Projects

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.